Literature DB >> 8919284

Rapid growth of hepatocellular carcinoma after or during interferon treatment of chronic hepatitis C: report of three cases.

A Onitsuka1, N Yamada, H Yasuda, T Miyata, T Kachi.   

Abstract

We report herein the cases of three patients in whom marked rapid growth of hepatocellular carcinoma (HCC) became evident after or during interferon (IFN) treatment for chronic hepatitis C. The HCC tumors were 10, 4.7, and 3.1 cm in size, and were found 7 months, 10 weeks, and 10 weeks after the initiation of IFN, respectively, in cases 1, 2, and 3. The clinical courses of these three patients suggest that the progression of HCC was more rapid during the IFN treatment period. Thus, we propose that abdominal ultrasonic (US) examination should be performed monthly in patients with chronic hepatitis who undergo IFN treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8919284     DOI: 10.1007/bf00311777

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  13 in total

1.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

2.  Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients.

Authors:  M Ebara; M Ohto; T Shinagawa; N Sugiura; K Kimura; S Matsutani; M Morita; H Saisho; Y Tsuchiya; K Okuda
Journal:  Gastroenterology       Date:  1986-02       Impact factor: 22.682

3.  Mechanism of the antitumour effect of interferon in mice.

Authors:  I Gresser; C Maury; D Brouty-Boyé
Journal:  Nature       Date:  1972-09-15       Impact factor: 49.962

4.  A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma. The Gastrointestinal Tumor Study Group.

Authors: 
Journal:  Cancer       Date:  1990-07-01       Impact factor: 6.860

5.  Epidemiology and long term prognosis of hepatitis C virus infection in Japan.

Authors:  M Yano; H Yatsuhashi; O Inoue; K Inokuchi; M Koga
Journal:  Gut       Date:  1993       Impact factor: 23.059

6.  Recombinant human gamma-interferon in primary hepatocellular carcinoma.

Authors:  A Forbes; P J Johnson; R Williams
Journal:  J R Soc Med       Date:  1985-10       Impact factor: 5.344

7.  Spontaneous regression of hepatocellular carcinoma: a case study.

Authors:  K C Lam; J C Ho; R T Yeung
Journal:  Cancer       Date:  1982-07-15       Impact factor: 6.860

8.  [A case of ruptured hepatocellular carcinoma with rapid growth after the interferon therapy in chronic hepatitis].

Authors:  A Onitsuka; H Yasuda; N Yamada; T Miyata; T Kachi
Journal:  Nihon Geka Gakkai Zasshi       Date:  1994-11

9.  Minute hepatocellular carcinoma without appreciable change in size for seven years: a case report.

Authors:  T Yoshida; N Okazaki; M Yoshino; H Kitaoka; S Hirohashi; Y Shimozato
Journal:  Cancer       Date:  1982-04-01       Impact factor: 6.860

10.  Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study.

Authors:  E Sachs; A M Di Bisceglie; G M Dusheiko; E Song; S F Lyons; B D Schoub; M C Kew
Journal:  Br J Cancer       Date:  1985-07       Impact factor: 7.640

View more
  2 in total

1.  Tripartite motif 24 (Trim24/Tif1α) tumor suppressor protein is a novel negative regulator of interferon (IFN)/signal transducers and activators of transcription (STAT) signaling pathway acting through retinoic acid receptor α (Rarα) inhibition.

Authors:  Johan Tisserand; Konstantin Khetchoumian; Christelle Thibault; Doulaye Dembélé; Pierre Chambon; Régine Losson
Journal:  J Biol Chem       Date:  2011-07-18       Impact factor: 5.157

2.  Suppression of signal transducers and activators of transcription 1 in hepatocellular carcinoma is associated with tumor progression.

Authors:  Atsushi Hosui; Peter Klover; Tomohide Tatsumi; Akio Uemura; Hiroaki Nagano; Yuichiro Doki; Masaki Mori; Naoki Hiramatsu; Tatsuya Kanto; Lothar Hennighausen; Norio Hayashi; Tetsuo Takehara
Journal:  Int J Cancer       Date:  2012-06-28       Impact factor: 7.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.